Back

Title	en A Randomized Controlled Trial Comparing the Effects of Sitagliptin and Glimepiride on Endothelial Function and Metabolic Parameters : Sapporo Athero-Incretin Study 1 (SAIS1)
Creator	en Nomoto, Hiroshi en Miyoshi, Hideaki NRID 1000030360902 en Furumoto, Tomoo NRID 1000010399925 en Oba, Koji NRID 1000030422926 en Tsutsui, Hiroyuki NRID 1000070264017 en Inoue, Atsushi en Atsumi, Tatsuya NRID 1000020301905 en Manda, Naoki en Kurihara, Yoshio en Aoki, Shin
Accessrights	open access
Rights	https://creativecommons.org/licenses/by/4.0/ en Creative Commons Attribution 4.0 International
Subject	NDC 490
Description	Abstract en Objectives; The DPP-4 inhibitors are incretin-related drugs that improve hyperglycemia in a glucose-dependent manner and have been reported to exert favorable effects on atherosclerosis. However, it has not been fully elucidated whether DPP-4 inhibitors are able to improve endothelial function in patients with type 2 diabetes. Therefore, we investigated the efficacy of sitagliptin, a DPP-4 inhibitor, on endothelial function and glycemic metabolism compared with that of the sulfonylurea glimepiride. Materials and Methods: In this multicenter, prospective, randomized parallel-group comparison study, 103 outpatients with type 2 diabetes (aged 59.9 +/- 9.9 years with HbA1c levels of 7.5 +/- 0.4%) with dietary cure only and/or current metformin treatment were enrolled and randomly assigned to receive sitagliptin or glimepiride therapy once daily for 26 weeks. Flow-mediated dilation (FMD), a comprehensive panel of hemodynamic parameters (Task Force(R) Monitor), and serum metabolic markers were assessed before and after the treatment. Results: During the study period, no statistically significant change in %FMD was seen in both groups (sitagliptin, 5.6 to 5.6%; glimepiride, 5.6 to 6.0%). Secretory units of islets in transplantation, TNF-α, adiponectin and biological antioxidant potential significantly improved in the sitagliptin group, and superoxide dismutase also tended to improve in the sitagliptin group, while improvements in HbA1c levels were similar between groups. Cardiac index, blood pressure and most other metabolic parameters were not different. Conclusions: Regardless of glycemic improvement, early sitagliptin therapy did not affect endothelial function but may provide favorable effects on beta-cell function and on inflammatory and oxidative stress in patients with type 2 diabetes without advanced atherosclerosis.
Publisher	en The Public Library of Science
Date	Issued2016-10-06
Language	eng
Resource Type	journal article
Version Type	VoR
Identifier	HDL http://hdl.handle.net/2115/63828
Relation	isIdenticalTo DOI https://doi.org/10.1371/journal.pone.0164255
Journal	PISSN 1932-6203 en PLoS ONE Volume Number11 Issue Number10 Page Starte0164255
File	fulltext journal.pone.0164255.pdf 862.48 KB (application/pdf) Issued2016-10-06 fulltext journal.pone.0164255.s001.DOCX 50.16 KB (application/msword) Issued2016-10-06 fulltext journal.pone.0164255.s002.DOCX 58.3 KB (application/msword) Issued2016-10-06 fulltext journal.pone.0164255.s003.DOC 134.5 KB (application/msword) Issued2016-10-06 fulltext journal.pone.0164255.s004.XLSX 40.17 KB (application/vnd.ms-excel) Issued2016-10-06 fulltext journal.pone.0164255.s005.XLSX 35.37 KB (application/vnd.ms-excel) Issued2016-10-06 fulltext journal.pone.0164255.s006.TIF 121.1 KB (image/tiff) Issued2016-10-06
Oaidate	2023-07-26